Net Pals Net Pals
Rezultatele cautarii
Vedeti tot
  • Conecteaza-te
    Conecteaza-te
    Inscrie-te
    Căutare
    Night Mode

Căutare

Descoperă oameni noi, creează noi conexiuni și faceti-va noi prieteni

  • News Feed
  • EXPLORE
  • Pagini
  • Grupuri
  • Events
  • Reels
  • Blogs
  • Anunturi
  • Offers
  • Jobs
  • Postari
  • Blogs
  • Utilizatori
  • Pagini
  • Grupuri
  • Events
  • EthanWalker a adăugat un sunet Alte
    2026-10-23 22:16:07 - Translate -
    Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in Europe
    Alvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...
    0 Commentarii 0 Distribuiri 10 Views 0 previzualizare
    Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
  • JamesWilson a adăugat un sunet Alte
    2026-10-23 19:43:53 - Translate -
    Ionis (IONS) partner Roche shows sefaxersen cut IgA nephropathy proteinuria 43.1% in Phase 3
    Roche gave the first effect size from its IMAgINATION kidney trial at ASN Kidney Week, a clearer read for Ionis Pharmaceuticals Inc. (IONS) on a partnered drug that carries milestones and royalties. Sefaxersen cut proteinuria by 43.1% against placebo at 37 weeks in a Phase 3 trial in IgA nephropathy, according to data Ionis Pharmaceuticals Inc. (IONS) released on October 23. Roche Holding AG,...
    0 Commentarii 0 Distribuiri 8 Views 0 previzualizare
    Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
  • RobertMitchell a adăugat un sunet Health
    2026-10-23 19:35:08 - Translate -
    Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease tests
    Roth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...
    0 Commentarii 0 Distribuiri 7 Views 0 previzualizare
    Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
© 2026 Net Pals Romaian
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
About Termeni Confidențialitate Cookies Acceptable Use Contacteaza-ne Director